Clinical trials: Severe Infection
Aspiration Pneumonia, Tracheostomy Complication
Intra-laryngeal Implant for Treatment of Chronic Aspirations
This study evaluates the medical device Newbreez LD is designed to protect the lower airways from saliva, liquids and food aspirations in tracheotomized patients suffering from chronic aspirations that require specific care and…
- Trial name
- NCT03325725
- Testing
- NewBreez LD intra-laryngeal implant
- Where
- 2 sites in France
- Sponsor
- ProTiP Medical
Severe Respiratory Syncytial Virus Infection
Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that…
- Trial name
- NCT01075178
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 2,036 people
- Sponsor
- Abbott
COVID-19, ARDS
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…
- Conditions
- COVID-19, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04452097
- Testing
- Human umbilical cord mesenchymal stem cells + best supportive care
- Sponsor
- Baylx Inc.
Ethmoid Sinusitis
Sinopsys Lacrimal Stent Indicated for Sinus Irrigation
The purpose of this study is to collect preliminary clinical data related to the safety and performance of the Sinopsys Lacrimal Stent.
- Trial name
- SLS (NCT02297243)
- Testing
- Sinopsys Lacrimal Stent
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Sinopsys Surgical
Hidradenitis Suppurativa (HS)
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT07244510
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Sepsis, Severe Sepsis
RCT of Sepsis Machine Learning Algorithm
The focus of this study will be to conduct a prospective, multi-center randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a machine-learning…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03882476
- Testing
- InSight
- Volunteers
- healthy volunteers welcome
- Sponsor
- Dascena
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.
Infection, Respiratory Tract
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic .
- Trial name
- NCT04435379
- Testing
- VPM1002
- Where
- 12 sites in Germany
- Volunteers
- 2,038 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Severe Sepsis
Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.
- Trial name
- OASIS (NCT01273779)
- Testing
- Talactoferrin alfa
- Where
- 100 sites in United States, Belgium and 8 more
- Volunteers
- 1,280 people
- Sponsor
- Agennix
Otitis Media
A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat
The purpose of the study is to assess the rate of elimination of bacteria by levofloxacin in middle ear fluid of children with a rapid and severe onset of infection and inflammation of the middle ear who are at high risk for…
- Trial name
- NCT00044473
- Testing
- levofloxacin
- Volunteers
- 206 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
Onychomycosis of Toenail
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution.
- Trial name
- NCT07065773
- Testing
- Trichostatin A
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanda Pharmaceuticals
Severe Sepsis
An Open Label Study of Severe Sepsis in Adults
This trial is to obtain safety data in adult patients with severe sepsis and two sepsis-induced organ infections who receive an infusion of drotrecogin alfa (activated).
- Trial name
- NCT00568893
- Testing
- drotrecogin alfa (activated)
- Where
- 18 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Pneumonia
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia.
- Trial name
- NCT04345614
- Testing
- Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2)
- Where
- 17 sites in United States
- Volunteers
- 314 people
- Sponsor
- CalciMedica, Inc.
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes.
- Trial name
- NCT05157243
- Testing
- Nitazoxanide, Vitamin Super-B Complex, Standard of Care
- Sponsor
- Romark Laboratories L.C.
COVID-19
Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)
In late December 2019, a new coronavirus strain emerged in China causing coronavirus disease 2019 (COVID-19). Since then, COVID-19 has become a global pandemic outbreak being declared a "public health emergency of international…
- Trial name
- CONDITION (NCT04389658)
- Where
- Spain
- Volunteers
- 1,526 people, healthy volunteers welcome
- Sponsor
- Igenomix
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2 Infection( COVID-19 )
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
- Trial name
- NCT04888949
- Testing
- Mesenchymal stem cell
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.